1 The role of Tc-99m DTPA aerosol scintigraphy in the differential diagnosis of COPD and asthma The Clinical Respiratory Journal, February 14, 2014
2 Qualitative assessment of attributes and ease of use of the ELLIPTATM dry powder inhaler for delivery of maintenance therapy for asthma and COPD BMC Pulmonary Medicine, December 13, 2013 Free full text
3 Impact of an integrated disease management program in reducing exacerbations in patients with severe asthma and COPD Respiratory Medicine, October 28, 2014
4 Mesenchymal stem cell therapy in lung disorders: Pathogenesis of lung diseases and mechanism of action of mesenchymal stem cell Experimental Lung Research, October 22, 2013 Review Article
5 Improvement in COPD management by access to asthma/COPD clinics in primary care: Data from the observational PATHOS study Respiratory Medicine, September 23, 2014
Question: Your patient is a 58-year-old male, a former smoker with moderate-to-severe COPD. He has enrolled in a clinical trial investigating losmapimod, a potent and selective inhibitor of p38 MAPK, and its effects on COPD exercise tolerance. Which statement about losmapimod is CORRECT?